A diffusable factor in Scottish coagulation factor concentrates can inhibit lymphocyte transformation in vitro.

Area of Science:

• Immunology
• Hematology
• Biochemistry

Background:

• Coagulation factor concentrates are used therapeutically.
• The immunomodulatory effects of these concentrates require further investigation.
• Previous studies have not fully elucidated the mechanisms behind potential lymphocyte inhibition.

Purpose of the Study:

• To investigate the effects of coagulation factor VIII and IX concentrates on human lymphocyte transformation.
• To determine the mechanisms responsible for any observed inhibition.

Main Methods:

• Human lymphocyte transformation assays were performed using lectins (concanavalin A, PHA) and a recall antigen (purified protein derivative of tuberculin, PPD).
• Coagulation factor concentrates, buffers, sodium citrate, and dialyzed concentrates were tested for inhibitory effects.
• Partially purified coagulation factor VIII was also assessed.

Main Results:

• Coagulation factor VIII and IX concentrates significantly inhibited lymphocyte transformation.
• Inhibition was largely independent of direct clotting factor-lectin interaction or simple toxicity.
• Dialysis substantially reduced the inhibitory activity of the concentrates.
• Concentrates' buffers and sodium citrate exhibited similar inhibitory effects.
• Partially purified factor VIII showed minimal inhibition.

Conclusions:

• The inhibitory effect of coagulation factor concentrates on lymphocyte transformation is primarily attributed to non-protein components, such as sodium citrate, rather than the clotting factors themselves.
• These findings suggest that the observed immunomodulation is likely due to the formulation buffer and not inherent properties of the coagulation factors.
• Further research is needed to confirm the specific inhibitory agents within the concentrate formulations.